Standard BioTools (LAB) Projected to Post Earnings on Tuesday

Key Points

• Q1 2026 results for Standard BioTools (NASDAQ:LAB) are due after the market close on Tuesday, May 5, with analysts forecasting EPS of ($0.02) and revenue of $17.8 million; the earnings call is scheduled for 4:30 PM ET.
• The company beat estimates in the prior quarter (reported $0.05 EPS vs. a -$0.03 consensus and $23.8M revenue vs. $18.5M expected) but continues to show weak profitability metrics, including a negative ROE (11.21%) and net margin (-59.39%).
• Analyst sentiment remains cautious with a consensus rating of "Reduce" and a $1.35 price target, even as institutional ownership is about 53.7% and several funds have recently increased their stakes.

Standard BioTools (NASDAQ:LAB - Get Free Report) is expected to post its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Standard BioTools to post earnings of ($0.02) per share and revenue of $17.80 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Standard BioTools (NASDAQ:LAB - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.08. Standard BioTools had a negative return on equity of 11.21% and a negative net margin of 59.39%.The firm had revenue of $23.80 million for the quarter, compared to analyst estimates of $18.50 million.

Standard BioTools Price Performance

Shares of NASDAQ:LAB opened at $0.90 on Tuesday. The business's 50 day moving average price is $0.98 and its 200-day moving average price is $1.23. Standard BioTools has a 1 year low of $0.87 and a 1 year high of $1.72. The firm has a market capitalization of $350.48 million, a price-to-earnings ratio of -4.49 and a beta of 1.42.

Analyst Ratings Changes

Several research analysts recently commented on the company. Wall Street Zen raised Standard BioTools from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. Weiss Ratings raised Standard BioTools from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus price target of $1.35.

Institutional Trading of Standard BioTools

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its stake in shares of Standard BioTools by 50.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company's stock worth $36,000 after acquiring an additional 9,986 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Standard BioTools by 4.4% in the 4th quarter. Deutsche Bank AG now owns 255,851 shares of the company's stock worth $327,000 after acquiring an additional 10,824 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Standard BioTools by 9.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 172,134 shares of the company's stock worth $221,000 after acquiring an additional 14,592 shares during the last quarter. Cerity Partners LLC increased its stake in shares of Standard BioTools by 70.2% in the 2nd quarter. Cerity Partners LLC now owns 37,501 shares of the company's stock worth $45,000 after acquiring an additional 15,470 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of Standard BioTools by 72.7% in the 2nd quarter. Prudential Financial Inc. now owns 39,307 shares of the company's stock worth $47,000 after acquiring an additional 16,541 shares during the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.

About Standard BioTools

Standard BioTools, Inc NASDAQ: LAB, formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.